STAAR Surgical’s (STAA) “Equal Weight” Rating Reiterated at Stephens

Stephens restated their equal weight rating on shares of STAAR Surgical (NASDAQ:STAA) in a report published on Wednesday,Benzinga reports. They currently have a $28.00 price target on the medical instruments supplier’s stock.

Several other research analysts have also recently issued reports on the stock. Piper Sandler lowered their target price on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday. Stifel Nicolaus lowered their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday. Mizuho cut shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $45.00 to $17.00 in a report on Wednesday. William Blair cut shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday. Finally, Needham & Company LLC restated a “hold” rating on shares of STAAR Surgical in a report on Wednesday. Two analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $26.86.

STAAR Surgical Stock Down 3.8 %

NASDAQ STAA opened at $15.35 on Wednesday. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $52.68. The stock has a market capitalization of $756.45 million, a PE ratio of 34.89 and a beta of 0.62. The firm has a 50 day moving average of $23.37 and a two-hundred day moving average of $28.97.

Insider Buying and Selling

In other news, major shareholder Broadwood Partners, L.P. acquired 23,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average price of $24.33 per share, for a total transaction of $559,590.00. Following the transaction, the insider now owns 10,848,631 shares in the company, valued at $263,947,192.23. This represents a 0.21 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders acquired a total of 402,024 shares of company stock worth $6,936,904 in the last 90 days. Company insiders own 1.00% of the company’s stock.

Hedge Funds Weigh In On STAAR Surgical

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in STAAR Surgical by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after buying an additional 319,441 shares during the last quarter. State Street Corp increased its holdings in shares of STAAR Surgical by 0.5% in the 3rd quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock valued at $72,092,000 after purchasing an additional 10,430 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new position in shares of STAAR Surgical in the 4th quarter valued at about $36,411,000. Geode Capital Management LLC increased its holdings in shares of STAAR Surgical by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after purchasing an additional 31,212 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of STAAR Surgical by 25.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 853,370 shares of the medical instruments supplier’s stock valued at $20,728,000 after purchasing an additional 171,046 shares in the last quarter. Hedge funds and other institutional investors own 96.70% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.